At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 47 enrolled
Drug / intervention
BMS-790052 +1 moredrug
Likely dose
BMS-790052 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of the Co-administration of BMS-790052 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri-Cyclen®) in Healthy Female Subjects
In Brief
A Phase 1 clinical trial evaluating BMS-790052 and Ortho Tri-Cyclen® for Chronic Hepatitis C. Completed, enrolled 47 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the effect of BMS-790052 on the pharmacokinetics of Ortho Tri-Cyclen® in healthy female subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionFeb 2010
TodayJul 2026
First PostedSep 24, 2009
Enrollment StartOct 1, 2009
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.8 years ago
Interventions
BMS-790052drug
Tablets, Oral, 60 mg, once daily, 10 days
Ortho Tri-Cyclen®drug
Tablets, Oral, once daily, 78 days